AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.
Original Article: AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals